Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

fuji pharmaceutical co.,ltd. - tretinoin - (reddish) yellow/red-brown capsule (major axis: approx. 10.0mm, minor axis: approx. 7.0mm)

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

esteve pharmaceuticals ltd - tretinoin - oral capsule - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - tretinoin - oral capsule - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

neon healthcare ltd - tretinoin - oral capsule - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - tretinoin - oral capsule - 10mg

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - minocycline -

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - doxycycline hyclate 115mg equivalent to doxycycline 100 mg;  ;  ;  ; doxycycline hyclate 115mg equivalent to doxycycline 100 mg; doxycycline hyclate 115mg equivalent to 100 mg doxycycline - film coated tablet - 100 mg - active: doxycycline hyclate 115mg equivalent to doxycycline 100 mg       excipient: carnauba wax colloidal silicon dioxide colour film coat 5511 magnesium stearate microcrystalline cellulose pregelatinised maize starch active: doxycycline hyclate 115mg equivalent to doxycycline 100 mg excipient: carnauba wax colloidal silicon dioxide diethyl phthalate ethanol hypromellose magnesium stearate microcrystalline cellulose opaspray yellow k-1f-6012b pregelatinised maize starch purified water active: doxycycline hyclate 115mg equivalent to 100 mg doxycycline excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose opadry yellow oy-ls-32814 pregelatinised maize starch - doxycycline is indicated in the treatment of uncomplicated chest, urethral, endocervical or rectal infections in adults caused by susceptible organisms (see actions) as shown by culture and sensitivity testing. it may also be a useful adjunct to amoebicides in acute intestinal amoebiasis and has a place as adjunctive therapy in severe acne.

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - tretinoin (unii: 5688utc01r) (tretinoin - unii:5688utc01r) - tretinoin 10 mg

United States - English - NLM (National Library of Medicine)

avkare - tretinoin (unii: 5688utc01r) (tretinoin - unii:5688utc01r) - tretinoin 10 mg - tretinoin capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (apl), french-american-british (fab) classification m3 (including the m3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the pml/rarα gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline-based chemotherapy is contraindicated. tretinoin capsules are for the induction of remission only. the optimal consolidation or maintenance regimens have not been defined, but all patients should receive an accepted form of remission consolidation and/or maintenance therapy for apl after completion of induction therapy with tretinoin capsules. tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. tretinoin capsules should not be given to patients who are sensitive to parabens, which are used as preservatives in the gelatin caps

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - minocycline hydrochloride dihydrate, quantity: 54 mg (equivalent: minocycline, qty 50 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; povidone; microcrystalline cellulose; sodium starch glycollate; sodium lauryl sulfate; titanium dioxide; hypromellose; indigo carmine; sunset yellow fcf; quinoline yellow; macrogol 400 - infections due to the following organisms, provided that they have been shown by bacteriological testing to be susceptible to minocycline: escherichia coli; enterobacter aerogenes; haemophilus influenzae; klebsiella and proteus. in addition, infections due to streptococcus pyogenes (group a beta-haemolytic) and streptococcus faecalis, however, because a large proportion of these organisms are resistant to tetracyclines, minocycline should be used only if the organisms have definitely been shown to be sensitive. tetracyclines, including minocycline, are not the drugs of choice in the treatment of staphylococcal infections. minocycline may be considered for the treatment of such infections only if other suitable agents are not available and the organism has been shown to be sensitive to minocycline. minocycline may be used in the treatment of tetracycline resistant acne.